Related Experiment Videos
99mTc colloid and 99mTc IDA imagings in diffuse hepatic disease
T Aburano1, K Yokoyama, N Shuke
1Department of Nuclear Medicine, Kanazawa University Hospital, Japan.
Journal of Clinical Gastroenterology
|December 1, 1993
Summary
Technetium-99m iminodiacetic acid (IDA) effectively assesses acute liver disease severity, while Technetium-99m colloid better identifies the cause and duration of chronic hepatic conditions.
Area of Science:
- Nuclear Medicine
- Hepatology
- Diagnostic Imaging
Background:
- Diffuse hepatic diseases encompass a range of conditions affecting liver function.
- Accurate diagnosis and staging are crucial for effective patient management.
- Radiopharmaceuticals like 99mTc colloid and 99mTc IDA are utilized in liver imaging.
Purpose of the Study:
- To compare the diagnostic utility of 99mTc colloid and 99mTc iminodiacetic acid (IDA) in patients with diffuse hepatic diseases.
- To evaluate the ability of each agent to determine disease etiology, chronicity, and severity.
Main Methods:
- Ninety-six patients with various diffuse hepatic diseases underwent imaging with both 99mTc colloid and 99mTc IDA.
- Data analysis focused on differentiating acute vs. chronic disease, identifying potential etiologies, and assessing disease severity.
Main Results:
- 99mTc IDA demonstrated higher sensitivity in depicting acute hepatic disease compared to 99mTc colloid.
- Both agents showed similar sensitivity for chronic hepatic disease.
- 99mTc colloid was superior for evaluating disease etiology and chronicity.
- 99mTc IDA effectively discriminated the severity of liver disease, particularly in cirrhosis.
Conclusions:
- 99mTc IDA is valuable for assessing functional disorders in acute liver disease and staging diffuse hepatic disease severity.
- 99mTc colloid excels in determining the etiology and chronicity of hepatic conditions.
- Combined use of both radiopharmaceuticals may offer comprehensive evaluation of diffuse hepatic diseases.